Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.

Asset list (PDF) Asset list (Excel)

Date Candidate Mechanism of action Indication Route Modality Development stage Note
01/11/19 GEM003 Selective glucocorticoid receptor agonist RA/OA, Please refer to Note Local Small molecules
Preclinical Updated on January 11, 2019

Expected to reduce unfavorable responses of glucocorticoids by selectivity of action (transrepression>transactivation)
Discontinued development for RA/OA. Available for repositioning.
Possible indications: Atopic dermatitis, Psoriasis, Asthma, COPD, Inflammatory bowel disease etc.
Contact
01/11/19 GEM002 Kappa-opioid receptor agonist Pain/Itching, Please refer to Note Oral Small molecules
Preclinical Updated on January 11, 2019

Discontinued development for pain because of company strategy. Available for repositioning.
Possible indications: Chronic pains (Back pain, Arthritis pain, Cancer pain, Post-herpetic neuralgia, Trigeminal neuralgia etc), Pruritus, Irritable bowel syndrome
Contact
01/11/19 GEM001 TRPV-1 agonist Rheumatoid Arthritis, Please refer to Note Oral Small molecules
Phase 2a Updated on January 11, 2019

Potently inhibits TNF-a production by oral administration.
Discontinued development for RA. Available for repositioning.
Possible indications: Neuropathic pain, Crohn’s disease, Systemic lupus erythematosus, Cachexia, Acute infectious disease, Allergy, Pyrexia, Anemia, Diabetes, Diseases related TNF-α (Colitis, Psoriasis ets.)
Contact
01/07/19 GEM062 Cannabinoid-releasing topical formulation (siustained release for about 24 hours) Chronic pain, Sclerosis, Lupus, others Topical Small molecule
Preclinical Cannabinoid’s utility: nausea and vomiting during chemotherapy, chronic pain, muscle spasms, epilepsy, sclerosis, lupus, schizophrenia etc.
This sustained-release topical formulation has significant potential to help treat these disorders. Preclinical efficacy demonstrated in a cutaneous lupus rodent model using AEA.
Contact
01/07/19 GEM061 Curcumin-releasing topical formulation (sustained release for about 24 hours) Please refer to Note Topical Small molecule
Preclinical Indication:
Osteoarthritis, CV disease, chronic inflammatory disease, vascular disease (Sickle Cell)

Note:
Curcumin’s utility: chronic pain, chronic inflammatory conditions such as osteoarthritis, vascular disease such as Sickle Cell and diabetes.
This formulation breaks through the limitations of the poor bioavailability of curcumin with oral administration. Preclinical efficacy demonstrated in an rodent arthritis model and a rodent diabetes model.
Contact
01/07/19 GEM060 Nitric Oxide-releasing topical formulation (sustained release for over 48 hours) Please refer to Note Topical Small molecules
Preclinical Indication:
Acne, Atopic Dermatitis, Fungal diseases, Wound healing, Chronic rhinosinusitis, Diabetic foot ulcers, Raynaud’s Phenomenon, Middle-ear infections, Erectile dysfunction, Others

Note:
NO function: Regulation of the vasculature (vasodilatory), broad spectrum antimicrobial activity, anti-inflammatory, anti-oxidant, wound healing, skin cell maturation and survival etc.
Human POC already shown with NO in onychomycosis, genital warts, moscullum contagiosum, pulmonary hypertension, acne, atopic dermatits (preliminary); animal POC demonstrated in over 20 peer-reviewed papers.
This formulation breaks through the limitations of sustained NO (topical) delivery.
Contact
12/27/18 GEM059 Recombinant Human Interleukin-1 Receptor Antagonist Please refer to Note IM Protein
Phase 1 Indication:
1: Infection, as manifested by febrile neutropenia, in patients with malignancies receiving chemotherapy drugs.
2: Diarrhea in patients with malignancies receiving chemotherapy drugs.
3. Gout arthritis

Note:
The world's first multiorgan protection agent for tumor chemotherapy.
Inhibits cell cycle progression of normal cells and renders them resistanace to chemotherapy.
No effects on tumor growth and their sensitivity to chemotherapy
Phase 1 : No dose limiting toxicity, None of subjects presented grade 3 or above chemotherapy-induced neutropenia or diarrhea.
Gout arthritis: Well tolerated and safe for patients who are restricted from NSAID, glucocorticoid, or colchicine.
Contact
12/27/18 GEM058 Increase cellular ATP and promote wound healing Diabetes foot ulcer Topical Small molecules
Phase 2 Reducing inflammation of endothelial cells of blood vessels.
Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. The arrangement of actin which is essential for cell migration is ATP dependent.
Applicable to all kind of wound and low cost treatment
Phase 2: The estimated complete closure rate is around 60% (vs placebo 30%)
Contact
12/27/18 GEM057 Increase hair follicle ATP and delay senescence of dermal papilla cells Alopecia Topical Small molecules
Phase 2 Boosts the ATP of human follicle dermal papilla cells, thereby slowing down the aging speed and prolonging hair cycle.
No side effects and shorter time to observe efficacy
Human trial (Androgenetic Alopecia): significantly improved 37.5% vs 0% (placebo) during 2 months
Phase 2 (Female pattern hair loss) : ongoing (comparison with minoxidil)
Contact
12/20/18 GEM056 Novel PDL1/CDx bispecific antibody Cancer with T cell inactivation and CDC inactivation Injection Proteins
Preclinical First bispecific combining the following two mechanisms: 1) Release cancer repression on T cell activation not only by blocking PDL1/PD1 interaction, but also by inducing PDL1 internalization into cancer cells; 2) Release cancer repression on CDC by downregulation of CDC repressor overexpressed by cancer cells (CDx is a CDC repressor overexpressed by multiple cancers, this bispecific can induce CDx internalization on cancer cells). Contact